$MNKD Andrea Leone-Bay, Receptor Life Sciences speaking engagement is getting close Wednesday September 16, 2020. 12.20 am Cannabinoids Delivered as Novel Solid Dosage Forms – Proof-of-Concept Clinical Data The effectiveness of cannabinoid medicines is negatively impacted by very low bioavailability, highly variable absorption, and erratic time to onset Currently available cannabinoid dosage forms attempt to compensate for some of these deficiencies with high doses that have the potential to produce undesirable side effects Receptor is developing solid dosage forms, both oral and inhaled, that address all of these cannabinoid delivery challenges. Data from 2 initial, proof-of-concept clinical studies will demonstrate the feasibility of this approach Andrea Leone-Bay, Chief Scientific Officer and Founder, Receptor Life Sciences international-cdp.com/whats...
  • 3
3 Likes